Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
Executive Summary
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: it won't have any real impact on industry. The bad news: it won't matter because pre-emption in the Rx arena was already dealt a body blow in the Supreme Court's recent ruling in Wyeth v. Levine